Clinical Trials | May 02, 2023
Lilly's Lebrikizumab shows improved face or hand dermatitis
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
Clinic will offer Comprehensive Genetic Counselling and Testing Services to empower patients with personalized care
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Apollo continues to invest in genomics technology and research for better patient care
Subscribe To Our Newsletter & Stay Updated
